Balchem Corp Liquidation Value

Balchem Corp (BCPC) as of March 31, 2026 presents a balance sheet that is deeply negative on a liquidation basis, consistent with its acquisition-driven capital structure. Total reported assets of $1.69B are dominated by goodwill ($811.5M, 47.9% of total assets) and finite-lived intangibles ($127.7M net), which receive zero recovery under liquidation assumptions. PP&E gross is $566.9M with accumulated depreciation of $263.8M, yielding net book value of $303.1M; at a 50-70% haircut, recoverable PP&E is roughly $151-212M. Cash and equivalents of $72.9M recover at 100%. AR of $154.2M (net of $1.1M allowance) recovers at 90-95%, yielding ~$139-146M. Inventory of $146.7M (net, with $3.5M reserve already applied) recovers at 60%, or ~$88M. Total haircutted asset recovery is estimated at roughly $450-530M before deducting liabilities at face value.

On the liability side, total reported liabilities are $408.6M. The revolving credit facility carries $169M outstanding under the 2022 Credit Agreement with $381M remaining available. Current liabilities total $152.5M. Deferred tax liabilities of $53.4M, operating lease obligations of $14.0M combined (current and non-current), unfunded benefit obligations ($1.1M postretirement medical, $0.9M Chemogas pension), and deferred compensation liability of $13.3M (offset by nearly equivalent rabbi trust assets) round out the long-term liability stack. Under liquidation, lease obligations ($15.7M present value of payments) and pension/OPEB liabilities remain at face value.

MFFAIS reports a cash liquidation value of -$91.7M, liquid liquidation value of $62.5M, and operating liquidation value of $209.2M, reflecting the progressive inclusion of less-liquid assets. These figures confirm the expected outcome: equity recovery is negative to marginally positive depending on the asset recovery tier applied. The dominant driver of the shortfall is the $811.5M goodwill balance (zero recovery) and $127.7M in finite-lived intangibles (zero recovery), together representing $939M of book value that contributes nothing in liquidation. No goodwill impairment was recognized this quarter. The revolving credit balance decreased modestly QoQ (prior period 10-K does not provide a direct March 2026 vs. December 2025 comparison, but MD&A discloses $52M drawn and $47M repaid in Q1 2026). The filing notes a subsequent repatriation of $23.5M from the Belgium subsidiary to pay down U.S. debt, which would reduce the revolver balance post-period. The Verona Superfund site and related ASAOC obligations remain contingent and unquantified; management asserts no material financial impact, but the remedial investigation is ongoing and the liability is not separately reserved on the balance sheet. Filing discusses the Superfund and ASAOC obligations in MD&A and Note 15 but does not separately tag or quantify a remediation accrual in XBRL.